EICHORPublic-registry site landscape for NCT04305444, “Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas”, a Relapsed Chronic Lymphocytic Leukemia study sponsored by Zhejiang DTRM Biopharma. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04305444 (registry record) |
| Study title | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas |
| Official title | Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas |
| Sponsor | Zhejiang DTRM Biopharma |
| Condition(s) | Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma |
| Phase | PHASE2 |
| Listed sites | 8 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04305444.
Eichor generates a preliminary site-risk snapshot for NCT04305444 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Relapsed Chronic Lymphocytic Leukemia trials
← Eichor home · All tracked trials · Relapsed Chronic Lymphocytic Leukemia studies · Weekly briefs
